Literature DB >> 1691691

Regulation of the human autologous T cell proliferation by endogenously generated C5a.

H Montz1, A Fuhrmann, M Schulze, O Götze.   

Abstract

The immunomodulating role of endogenously synthesized C5 and subsequently generated C5a was studied in a serum-free human autologous mixed leukocyte reaction (AMLR) using either separated T and non-T cell populations or unfractionated mononuclear leukocytes of human peripheral blood. Monoclonal mouse IgG or Fab fragments against human C5/C5a were used as probes for the evaluation of the biological effects of C5a. The reduction of DNA synthesis after the addition of nanogram amounts of anti-C5/C5a mAb was dose-dependent, reaching maximum levels of 30-50%. Of special importance was the availability of a mAb that recognizes a neoepitope present on C5a and not on serum-derived C5. The demonstration of the specificity of its inhibitory effect suggests that C5 is synthesized under the in vitro conditions employed and that the subsequently generated C5a exerts biological effects on T cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691691     DOI: 10.1016/0008-8749(90)90137-g

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

1.  The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1.

Authors:  H Montz; K C Koch; R Zierz; O Götze
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

Review 2.  New insights into the immune functions of complement.

Authors:  Edimara S Reis; Dimitrios C Mastellos; George Hajishengallis; John D Lambris
Journal:  Nat Rev Immunol       Date:  2019-08       Impact factor: 53.106

3.  Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.

Authors:  Sam D Sanderson; Marilyn L Thoman; Kornelia Kis; Elizabeth L Virts; Edgar B Herrera; Stephanie Widmann; Homero Sepulveda; Joy A Phillips
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.